Pharma BD Deal Intelligence

Cephalon Inc. / Laboratoire L. Lafon S.A. (Group Lafon)

2000 · Acquisition/Merger · $450M · Complete

Announcement Sentiment

Positive

Cephalon announced agreement Dec 2000 to acquire France's Group Lafon for $450M cash, securing worldwide modafinil (Provigil) rights and the API manufacturing site (Mitry-Mory). Closed in December 2001 after share-purchase amendment.

Did it work? Outcome assessment

Strategic verdict

Achieved Stated Rationale

Financial impact

Accretive

Pipeline outcome

Assets Advanced

Assessment window: 15yr post-close.

Key facts

Announced Dec 15, 2000
Closed Dec 28, 2001
Deal value $450M
Deal type Acquisition/Merger
Therapeutic area Narcolepsy, excessive daytime sleepiness
Indications Narcolepsy, excessive daytime sleepiness
Key assets Modafinil (Provigil) worldwide rights and active ingredient
Mechanism Wake-promoting agent (atypical dopamine reuptake)

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals